Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellyan Biotechnology CoHKPD -4.33%21 Operating Margin % is 2.96% as of Sep. 2025, which is 66% below its 10-year median of 8.58. GuruFocus rates HKPD with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 117 Medical Distribution companies, Cellyan Biotechnology Co ranks worse than 83.76% on this metric.
Cellyan Biotechnology Co (NAS:HKPD) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Cellyan Biotechnology Co Operating Margin % Related Terms
Cellyan Biotechnology Co Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKPD vs COSM, SNYR, YI: Operating Margin % Comparison
For the Medical Distribution subindustry, Cellyan Biotechnology Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellyan Biotechnology Co Operating Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cellyan Biotechnology Co's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Cellyan Biotechnology Co's Operating Margin % falls into.
Cellyan Biotechnology Co Operating Margin % Calculation
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Cellyan Biotechnology Co's Operating Margin % for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellyan Biotechnology Co (HKPD) has a Operating Margin % of 2.96% as of Sep. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Cellyan Biotechnology Co and its competitors. This is 66% below median its historical median of 8.58. According to the industry distribution chart, Cellyan Biotechnology Co ranks #98 out of 117 companies in the Medical Distribution industry, placing it in the top 83.8%.
Is Cellyan Biotechnology Co's Operating Margin % too high?
Cellyan Biotechnology Co's current Operating Margin % of 2.96% is 66% below median its 10-year median of 8.58. The Medical Distribution industry median Operating Margin % is 3.05. Cellyan Biotechnology Co's value of 2.96% is 3% below this industry median. Based on the distribution chart, Cellyan Biotechnology Co ranks #98 out of 117 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cellyan Biotechnology Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's Operating Margin % compare to COSM and SNYR?
According to the Medical Distribution industry distribution chart, Cellyan Biotechnology Co ranks #98 out of 117 companies for Operating Margin %. This places Cellyan Biotechnology Co in the lower half of its industry. The industry median Operating Margin % is 3.05. Cellyan Biotechnology Co's value of 2.96% is 3% below this benchmark. While the company's 10-year median is 8.58 vs. the industry median of 3.05, Cellyan Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Distribution company?
The median Operating Margin % among Medical Distribution companies is 3.05, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cellyan Biotechnology Co's current Operating Margin % of 2.96% is 3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Cellyan Biotechnology Co and its competitors. For the Medical Distribution industry, the median Operating Margin % is 3.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellyan Biotechnology Co's current Operating Margin % is 2.96%, which is 66% below median its own 10-year median of 8.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current Operating Margin % of 2.96%. The current Operating Margin % is 2.96%, which is 66% below median its 10-year median of 8.58 and 3% below the Medical Distribution industry median of 3.05. Cellyan Biotechnology Co's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current Operating Margin % is 2.96% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
21GF Score
Get the complete analysis for HKPD
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKPD has been successfully added to your 
